View More
Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Nilofer S. Azad, MD, and Kanwal Raghav, MD, discuss current and emerging uses of regorafenib and TAS-102 in later-line treatment of patients with mCRC, with topics including:
Associate Professor, Oncology
Johns Hopkins
Baltimore, Maryland
Associate Professor
GI Medical Oncology
University of Texas MD Anderson Cancer Center
Houston, Texas
This program has been made available online.
Phase I/II ReFocus: RLY-4008 in patients with FGFR inhibitor-naive cholangiocarcinoma with FGFR2 alterations, presented at ESMO 2022 and reported by Clinical Care Options (CCO)
From Clinical Care Options (CCO), download slides reviewing contemporary systemic therapy for HCC and BTC
James M. Cleary, MD, PhD
Mark Yarchoan, MD
Released: September 19, 2022
Primary results from phase III LEAP-002 study of lenvatinib with or without pembrolizumab as first-line treatment for patients with advanced hepatocellular carcinoma, presented at ESMO 2022 and reported by Clinical Care Options (CCO)
Experts highlight key studies being reported at the upcoming 2022 ESMO Congress in this commentary from Clinical Care Options (CCO)
Nicoletta Colombo, MD
Robert Motzer, MD
David Planchard, MD, PhD
Elizabeth R. Plimack, MD, MS
Rachna Shroff, MD
Sara Tolaney, MD, MPH
Released: September 8, 2022
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.